ACE Stock Overview
A biotech company, focuses on orphan oncology treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ascelia Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.67 |
| 52 Week High | SEK 17.98 |
| 52 Week Low | SEK 2.00 |
| Beta | 1.03 |
| 11 Month Change | 20.86% |
| 3 Month Change | 18.18% |
| 1 Year Change | -7.14% |
| 33 Year Change | -91.12% |
| 5 Year Change | -86.81% |
| Change since IPO | -89.29% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?
Nov 09
Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?
May 31Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?
May 11Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans
Aug 05We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Jan 24We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Aug 23Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth
May 19Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like
Mar 07Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares
Dec 09We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Nov 26Shareholder Returns
| ACE | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 2.9% | -5.8% | -2.1% |
| 1Y | -7.1% | 14.3% | 10.8% |
Return vs Industry: ACE underperformed the Swedish Biotechs industry which returned 17.8% over the past year.
Return vs Market: ACE underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
| ACE volatility | |
|---|---|
| ACE Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ACE's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ACE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 13 | Magnus Corfitzen | www.ascelia.com |
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 trial for the treatment of gastric cancer.
Ascelia Pharma AB (publ) Fundamentals Summary
| ACE fundamental statistics | |
|---|---|
| Market cap | SEK 252.21m |
| Earnings (TTM) | -SEK 62.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.1x
P/E RatioIs ACE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACE income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 62.30m |
| Earnings | -SEK 62.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 07, 2025
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 24.4% |
How did ACE perform over the long term?
See historical performance and comparison